U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 1391 - 1400 of 21518 results

Status:
Investigational
Source:
INN:forfenimex
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)


Forfenimex (also known as forphenicinol), a low molecular weight immunomodifier was studied as an antineoplastic agent. Preclinical experiments in vitro have shown that forfenimex enhanced the antitumor effects of cyclophosphamide in a model of squamous cell carcinoma. Experiments on rodents have revealed that this compound possessed protective effect against P. aeruginosa infection. This influence achieved due to macrophage activation followed by the enhancement of the bactericidal activity of polymorphonuclear cells (PMN).
Status:
Investigational
Source:
NCT02265289: Phase 1 Interventional Completed Healthy
(1999)
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)



Lefradafiban, an orally active prodrug of fradafiban, is a novel glycoprotein (IIb/IIIa) inhibitor for the treatment of unstable angina. The pharmacokinetic and pharmacodynamic properties of lefradafiban were assessed in 130 healthy male volunteers who received a single dose of 10, 50, 75, 100, or 150 mg or multiple doses of 25, 50, 60, 75, 90, or 100 mg three times daily for one week. After both single and multiple doses, receptor occupancy and plasma lefradafiban levels correlated with platelet aggregation. Lefradafiban had been in phase II clinical trials by Boehringer Ingelheim for the treatment of thrombosis. However, it has been terminated.
Status:
Investigational
Source:
INN:estrofurate
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Estrofurate (AY-11483) is an impeded estrogen. it prevents ovulation and implantation.
Status:
Investigational
Source:
INN:irtemazole [INN]
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)

IRTEMAZOLE is a uricosuric agent exhibiting a rapid uricosuric effect in normouricemic as well as in hyperuricemic persons.
Status:
Investigational
Source:
INN:acetorphine
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Acetorphine is a synthetic narcotic analgesic. Acetorphine was reported to have uses in veterinary medicine with pronounced advantages in the immobilization of the giraffe in which toxic effects were reduced as compared to the effects of etorphine. In July 1966, the Director-General of the World Health Organization informed the Secretary-General that WHO had arrived at the conclusion that etorphine and acetorphine should be included in Schedule I of the Convention, since they could give rise to similar abuse, and produce similar ill effects as the substances already listed therein. Acetorphine is a Schedule I controlled substance in the United States.
Status:
Investigational
Source:
INN:brofezil
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)


Brofezil (ICI 54594) is an ibuprofen derivative with anti-inflammatory and analgesic activity.
Status:
Investigational
Source:
INN:iolidonic acid
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)

Iolixanic Acid is triiodophenoxyalkoxyalkanoic acid derivative patented by Bracco Industria Chimica S.p.A. as diagnostic agent for cholecystography.
Status:
Investigational
Source:
NCT01128335: Phase 2 Interventional Completed Liver Transplantation
(2010)
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)



Sotrastaurin, an orally-active, first-in-class immunomodulator, is under development by Novartis for the treatment of uveal melanoma and diffuse-large B-cell lymphoma. Sotrastaurin is a low molecular mass synthetic compound that potently inhibits the PKC α, β and the θ isoforms resulting in selective NF-κB inactivation. Sotrastaurin is a potent and selective pan-PKC inhibitor, mostly for PKCθ with Ki of 0.22 nM in a cell-free assay. Inhibition of PKC beta in B-cells results in prevention of NF-kB-mediated signaling and down regulation of NF-kB target genes. This may eventually lead to an induction of G1 cell cycle arrest and tumor cell apoptosis in susceptible tumor cells. This agent may act synergistically with other chemotherapeutic agents. PKC, a family of serine/threonine protein kinases overexpressed in certain types of cancer cells, is involved in cell differentiation, mitogenesis, inflammation, and the activation and survival of lymphocytes. Sotrastaurin is currently in phase II trials by Novartis for the treatment of large B-cell lymphoma and uveal melanoma. Sotrastaurin was in Phase II of clinical development for the prevention of acute rejection after solid organ transplantation and psoriasis, but this reseach had being discontinued.
Status:
Investigational
Source:
INN:pretiadil
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)

Pretiadil is a thiadiazepine dioxide derivative patented by American pharmaceutical company Bristol-Myers Co. as a coronary vasodilating compound.
Status:
Investigational
Source:
INN:oxprenoate potassium [INN]
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Showing 1391 - 1400 of 21518 results